603579 荣泰健康
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入400,6143.86%1,855,0292,004,8212,612,5702,020,516
减:营业总成本331,559-6.94%1,641,6151,828,5832,402,4101,826,662
    其中:营业成本256,891-5.83%1,283,2411,473,0691,911,4661,440,574
               财务费用(8,021)-248.89%(14,889)(21,450)36,44630,741
               资产减值损失(324)-183.70%(6,615)(3,285)(1,192)(2,765)
公允价值变动收益640-111.20%(16,219)10,4104,6947,050
投资收益(1,932)-113.73%29,26419,57194,80217,872
    其中:对联营企业和合营企业的投资收益358-172.31%1,5352133,366(5,501)
营业利润69,25459.72%235,955186,537265,225200,362
利润总额69,26459.02%230,192179,373260,964198,172
减:所得税费用6,4169.09%26,86014,65332,93117,205
净利润62,84766.81%203,332164,720228,034180,966
减:非控股权益106-39.37%625492(8,302)(12,035)
股东净利润62,74267.31%202,707164,228236,336193,001

市场价值指针
每股收益 (元) *0.47067.86%1.5101.2301.7501.420
每股派息 (元) *----1.0000.5000.7000.500
每股净资产 (元) *14.4628.79%13.85913.02612.38211.547
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容